RESUMEN
With the morbidity and mortality associated with the COVID-19 pandemic that we are witnessing this year, the risks posed by emerging viral diseases to global health are all too obvious. This pandemic highlights the importance of antiviral drug discovery, which targets emerging viral pathogens, as well as existing pathogenic viruses that undergo continuous evolution. Drug discovery and development is a long and resource intensive process; however, the use of biomarkers can accelerate clinical development of antivirals by providing information regarding diagnosis of specific viral infections, status of infection, potential safety parameters, and antiviral responses. In clinical practice, many of the biomarkers initially utilized to support clinical development are also used for patient care. While viral load is a standard and essential biomarker used to detect the desired viral suppression induced by an antiviral agent, it has become apparent that additional biomarkers, whether related to the virus, the host or as a consequence of the drug's mechanistic effects, are also important for monitoring clinical outcomes associated with an antiviral therapy. This review summarizes the biomarkers used in the clinical development (as well as in clinical practice, where appropriate) of antiviral therapies for hepatitis C virus, hepatitis B virus, human immunodeficiency virus, and severe acute respiratory syndrome coronavirus 2.
Asunto(s)
Antivirales/uso terapéutico , Biomarcadores/análisis , Virosis/tratamiento farmacológico , Animales , Antivirales/farmacología , COVID-19/virología , Ensayos Clínicos como Asunto , Humanos , SARS-CoV-2/fisiología , Tratamiento Farmacológico de COVID-19RESUMEN
Preventing entry of HIV into human host cells has emerged as an attractive approach to controlling viral replication. Maraviroc 1 is an approved antagonist of the human CCR5 receptor which prevents the entry of HIV. Herein, we report the design and discovery of a series of imidazopiperidine CCR5 antagonists which retain the attractive antiviral profile and window over hERG activity of maraviroc 1, combined with improved absorption profiles in rat and dog. Furthermore, this series of compounds has been shown to retain activity against a laboratory generated maraviroc-resistant HIV-1 strain, which indicates an alternative resistance profile to that of maraviroc 1. Compound 41f (PF-232798) was selected as a clinical candidate from the imidazopiperidine series and is currently in phase II clinical trials.
Asunto(s)
Fármacos Anti-VIH/síntesis química , Compuestos de Azabiciclo/síntesis química , Antagonistas de los Receptores CCR5 , VIH-1/efectos de los fármacos , Imidazoles/síntesis química , Animales , Fármacos Anti-VIH/química , Fármacos Anti-VIH/farmacología , Compuestos de Azabiciclo/química , Compuestos de Azabiciclo/farmacología , Línea Celular , Cricetinae , Ciclohexanos/farmacología , Perros , Farmacorresistencia Viral , Canal de Potasio ERG1 , Canales de Potasio Éter-A-Go-Go/metabolismo , VIH-1/aislamiento & purificación , Humanos , Imidazoles/química , Imidazoles/farmacología , Leucocitos Mononucleares/efectos de los fármacos , Leucocitos Mononucleares/virología , Maraviroc , Modelos Moleculares , Unión Proteica , Ratas , Estereoisomerismo , Relación Estructura-Actividad , Triazoles/farmacología , TropanosRESUMEN
A genetic approach utilizing the yeast Saccharomyces cerevisiae was used to identify the target of antifungal compounds. This analysis led to the identification of small molecule inhibitors of RNA polymerase (Pol) III from Saccharomyces cerevisiae. Three lines of evidence show that UK-118005 inhibits cell growth by targeting RNA Pol III in yeast. First, a dominant mutation in the g domain of Rpo31p, the largest subunit of RNA Pol III, confers resistance to the compound. Second, UK-118005 rapidly inhibits tRNA synthesis in wild-type cells but not in UK-118005 resistant mutants. Third, in biochemical assays, UK-118005 inhibits tRNA gene transcription in vitro by the wild-type but not the mutant Pol III enzyme. By testing analogs of UK-118005 in a template-specific RNA Pol III transcription assay, an inhibitor with significantly higher potency, ML-60218, was identified. Further examination showed that both compounds are broad-spectrum inhibitors, displaying activity against RNA Pol III transcription systems derived from Candida albicans and human cells. The identification of these inhibitors demonstrates that RNA Pol III can be targeted by small synthetic molecules.